10362-14-8

Usage

Appearance

White crystalline solid

Solubility

Insoluble in water, soluble in organic solvents

Uses

Antioxidant in rubber and lubricants

Function

Inhibits oxidation process, prevents degradation, extends shelf life

Toxicity

Toxic, can cause skin and eye irritation

Environmental impact

Potentially harmful to aquatic organisms and the environment

Handling precautions

Handle with caution, proper management required to minimize environmental impact

Upstream product

• 253185-03-4 tert-butylbenzene 
• 4160-54-7 1-tert-butyl-2,4-dinitrobenzene 

Downstream Products

• 873055-97-1 (4-tert-butyl-3-formylaminophenyl)carbamic acid benzyl ester 
• 873055-96-0 (3-amino-4-tert-butyl-phenyl)-carbamic acid benzyl ester 
• 873055-99-3 4-tert-butyl-N³-methylbenzene-1,3-diamine 
• 873055-98-2 N-(5-amino-2-tert-butylphenyl)formamide 

Relevant academic research and scientific papers

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.